Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Narra J
Francesco Rosiello
Department of Public Health and Infectious Disease, Sapienza-University of Rome, Rome, Italy
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Persistence of long COVID symptoms in COVID-19 survivors worldwide and its potential pathogenesis - A systematic review and meta-analysis Marhami Fahriani; Muhammad Ilmawan; Jonny K. Fajar; Helnida A. Maliga; Andri Frediansyah; Sri Masyeni; Hanifah Yusuf; Firzan Nainu; Francesco Rosiello; Salin Sirinam; Synat Keam; Youdiil Ophinni
Narra J Vol. 1 No. 2 (2021): August 2021
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narraj.v1i2.36

Abstract

The study sought to determine the prevalence of persistent long COVID symptoms such as anxiety, depression, dizziness, chest pain, sleep difficulty, palpitations, weight loss, and hair loss among coronavirus disease 2019 (COVID-19) survivors worldwide and to discuss the potential pathogeneses. Potential studies were searched in three databases (PubMed, Scopus, and Web of Science) as of January 30, 2021. Data on study characteristics, patient characteristics during the follow-up, the number of patients with persistent long COVID symptoms and total COVID-19 survivors were collected according to PRISMA guidelines. To assess the quality of studies, the Newcastle-Ottawa scale was used. The estimated prevalence of each long COVID symptom and the association between COVID-19 severity and the occurrence of prolonged symptoms was assessed, if appropriate. The global prevalence of prolonged anxiety was 15.76% (95%CI: 6.36%, 25.15%). Chest pain persisted in 10.36% (239/3,224) of COVID-19 patients (95%CI: 4.92%, 15.80%). Prolonged depression was found in 24 of 548 COVID-19 survivors with an estimated prevalence of 4.32% (95%CI: 2.62%, 6.03%) and dizziness was presented in 4.83% (118/2,219, 95%CI: 1.50%, 8.16%) after recovery. Hair loss was complained by 527 of 2,251 recovered patients (cumulative prevalence of 24.76%, 95%CI: 19.60%, 29.91%), while weight loss was identified in 37 cases among 452 COVID-19 survivors (8.19%, 95%CI: 5.66%, 10.71%). Prolonged palpitation was experienced by 19.38% (211/1,926) survivors with 95%CI: 2.40%, 41.16%. Sleep difficulty was found in 541 of 2,622 COVID-19 survivors (17.87%, 95%CI: 7.55%, 28.20%). The association between COVID-19 severity and the occurrence of persistent long COVID symptoms was not analyzed due to the lack of data. In conclusion, persistent psychological symptoms are frequently reported among COVID-19 survivors. Follow-up studies with a longer duration and larger population are warranted to assess the extent of prolonged symptoms and the quality of life of COVID-19 survivors. Despite various potential pathogeneses that have been hypothesized, a definitive mechanism is yet to be addressed.
Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis Jhonny K. Fajar; Muhammad Ilmawan; Sukamto Mamada; Endang Mutiawati; Milda Husnah; Hanifah Yusuf; Firzan Nainu; Salin Sirinam; Synat Keam; Youdiil Ophinni; Francesco Rosiello; Marhami Fahriani; Sandro GV. Rosa
Narra J Vol. 1 No. 3 (2021): December 2021
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v1i3.48

Abstract

This study was conducted to determine the prevalence of prolonged neuromuscular symptoms, including fatigue, anosmia, headache, myalgia, and joint pain in COVID-19 survivors hospitalized with mild, moderate, or severe infections worldwide. The search was conducted up to January 30th, 2021 using three databases (PubMed, Scopus, and Web of Science) to identify potentially eligible studies. Data on study characteristics, follow-up characteristics, and severity of COVID-19 during hospitalization were collected in accordance with PRISMA guidelines. The Newcastle-Ottawa scale was used to assess the quality of relevant articles. The estimated prevalence of specific prolonged neuromuscular symptoms and the association between COVID-19 severity and occurrence of prolonged neuromuscular symptoms was analyzed wherever appropriate. Database search yielded 4,050 articles and 22 articles were included for meta-analysis. The estimated prevalence of prolonged fatigue was recorded in 21.2% (95%CI: 11.9%–34.8%) of 3,730 COVID-19 survivors. Persistent anosmia was recorded in 239 of 2,600 COVID-19 survivors (9.7%, 95%CI: 6.1%–15.2%). In 84 out of 2,412 COVID-19 survivors (8.9%, 95%CI: 3.2%–22.6%), prolonged headache was observed. A total of 53 out of 1,125 COVID-19 patients (5.6%, 95%CI: 2.1%–14.2%) complained of persistent myalgia even after being discharged from the hospital. The prevalence of prolonged joint pain was in 15.4% (95%CI: 8.2%–27.2%) of subjects. Due to data scarcity on COVID-19 severity and prolonged neuromuscular symptoms, association analysis could not be conducted. Widespread concern regarding long-term impacts of COVID-19 was raised after several studies reported prolonged symptoms in COVID-19 survivors. Numerous theories have been proposed to address this concern; however, as the research on this pandemic is still ongoing, no explanation is definitive yet. Therefore, follow-up studies in COVID-19 survivors after recovery from COVID-19 are warranted to determine the pathogenesis of prolonged symptoms. PROSPERO registration: CRD42021242332.
Willingness-to-pay for COVID-19 vaccine in ten low-middle-income countries in Asia, Africa and South America: A cross-sectional study Malik Sallam; Samsul Anwar; Amanda Yufika; Marhami Fahriani; Milda Husnah; Hendrix I. Kusuma; Rawan Raad; Namareg ME. Khiri; Rashed YA. Abdalla; Rashed Y. Adam; Mohajer IH. Ismaeil; Asma Y. Ismail; Wajdi Kacem; Zeineb Teyeb; Khaoula Aloui; Montacer Hafsi; Nesrine Ben Hadj Dahman; Manel Ferjani; Dalia Deeb; Dina Emad; Farah S. Sami; Kirellos Said Abbas; Fatma A. Monib; Subramaniam R; Suhrud Panchawagh; Khan Sharun; Sunil Anandu; Mahir Gachabayov; Md A. Haque; Talha B. Emran; Guilherme W. Wendt; Lirane ED. Ferreto; María F. Castillo-Briones; Rocío B. Inostroza-Morales; Sebastián A. Lazcano-Díaz; José T. Ordóñez-Aburto; Jorge E. Troncoso-Rojas; Emmanuel O. Balogun; Akele R. Yomi; Abiodun Durosinmi; Esther N. Adejumo; Eyiuche D. Ezigbo; Morteza Arab-Zozani; Elham Babadi; Edris Kakemam; Irfan Ullah; Najma I. Malik; Deema Dababseh; Francesco Rosiello; Seyi S. Enitan
Narra J Vol. 2 No. 1 (2022): April 2022
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v2i1.74

Abstract

Vaccine hesitancy is considered as one of the greatest challenges to control the ongoing coronavirus disease 2019 (COVID-19) pandemic. A related challenge is the unwillingness of the general public to pay for vaccination. The objective of this study was to determine willingness-to-pay (WTP) for COVID-19 vaccine among individuals from ten low-middle-income countries (LMICs) in Asia, Africa, and South America. Data were collected using an online questionnaire distributed during February - May 2021 in ten LMICs (Bangladesh, Brazil, Chile, Egypt, India, Iran, Nigeria, Pakistan, Sudan, and Tunisia). The major response variable of in this study was WTP for a COVID-19 vaccine. The assessment of COVID-19 vaccine hesitancy was based on items adopted from the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) vaccine hesitancy scale constructs. In this study, 1337 respondents included in the final analysis where the highest number of respondents was from India, while the lowest number was from Egypt. A total of 88.9% (1188/1337) respondents were willing to pay for the COVID-19 vaccination, and 11.1% (149/1337) were not. The average WTP for COVID-19 vaccination was 87.9 US dollars ($), (range: $5-$200). The multivariate model analysis showed that the country, monthly household income, having a history of respiratory disease, the agreement that routine vaccines recommended by health workers are beneficial and having received the flu vaccination within the previous 12 months were strongly associated with the WTP. Based on the country of origin, the highest mean WTP for COVID-19 vaccine was reported in Chile, while the lowest mean WTP for the vaccine was seen among the respondents from Sudan. The availability of free COVID-19 vaccination services appears as a top priority in the LMICs for successful control of the ongoing pandemic. This is particularly important for individuals of a lower socio-economic status. The effects of complacency regarding COVID-19 extends beyond vaccine hesitancy to involve less willingness to pay for COVID-19 vaccine and a lower value of WTP for the vaccine.
Co-Authors Abiodun Durosinmi Akele R. Yomi Amanda Yufika Andri Frediansyah Asma Y. Ismail Dalia Deeb Deema Dababseh Dina Emad Edris Kakemam Elham Babadi Emmanuel O. Balogun Endang Mutiawati Rahayuningsih* Esther N. Adejumo Eyiuche D. Ezigbo Farah S. Sami Fatma A. Monib Firzan Nainu Firzan Nainu Guilherme W. Wendt HANIFAH YUSUF Helnida A. Maliga Hendrix I. Kusuma Irfan Ullah Jhonny K. Fajar Jonny K. Fajar Jorge E. Troncoso-Rojas José T. Ordóñez-Aburto Khan Sharun Khaoula Aloui Kirellos Said Abbas Lirane ED. Ferreto Mahir Gachabayov Malik Sallam Manel Ferjani Marhami Fahriani Marhami Fahriani María F. Castillo-Briones Md A. Haque Milda Husnah Milda Husnah Mohajer IH. Ismaeil Montacer Hafsi Morteza Arab-Zozani Muhammad Ilmawan Muhammad Ilmawan Najma I. Malik Namareg ME. Khiri Nesrine Ben Hadj Dahman Rashed Y. Adam Rashed YA. Abdalla Rawan Raad Rocío B. Inostroza-Morales Salin Sirinam Samsul Anwar Sandro GV. Rosa Sebastián A. Lazcano-Díaz Seyi S. Enitan Sri Masyeni, Dewa Ayu Putri Subramaniam R Suhrud Panchawagh Sukamto Mamada Sunil Anandu Synat Keam Talha B. Emran Wajdi Kacem Youdiil Ophinni Youdiil Ophinni Zeineb Teyeb